Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3403-3411

  Smith, Roy E ^a   Brown, Ann M ^a   Mamounas, Eleftherios P ^a   Anderson, Stewart J ^a   Lembersky, Barry C ^a   Atkins, James H ^a   Shibata, Henry R ^a   Baez, Luis ^a   DeFusco, Patricia A ^a   Davila, Enrique ^a   Tipping, Stuart J ^a   Bearden, James D ^a   Thirlwell, Michael P ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MYALGIA; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0032751111     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3403     Document Type: Article

References (31)

1. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247-256, 1995
2. Hainsworth J, Greco A: Paclitaxel administered by 1-hour infusion: Preliminary results of a phase I/II trial comparing two schedules. Cancer 74:1377-1382, 1994
3. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
4. Nabholtz J-M, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
5. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
6. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995
7. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
8. Wilson WH, Berg S, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
9. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1997
10. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 77:1561-1565, 1980
11. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
12. Burris HA III: Preclinical pharmacology and phase I clinical trials. Ann Pharmacother 28:7-10, 1994 (suppl 5)
13. Reichman B, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
14. Vermorken JB, ten Bokkel Huinink WW, Mandjes I, et al: High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A European Cancer Center trial. Semin Oncol 22:16-22, 1995
15. Swenerton K, Eisenhower E, ten Bokkel Huinink WW, et al: Taxol in relapsed ovarian cancer: High-vs low-dose and short-vs long-infusion: A European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 12:256, 1993 (abstr 810)
16. Schiller JH, Tutsch K, Aroomanian R, et al: Phase I trial of a 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
17. Mamounas E, Brown A, Fisher B, et al: 3-hr high-dose Taxol (T) infusion in advanced breast cancer (CABC): An NSABP phase II study. Proc Am Soc Clin Oncol 14:127, 1995 (abstr 206)
18. Martoni A, Zamagni C, Gheka A, et al: Anthistimines in the treatment of Taxol-induced paroxystic pain syndrome. J Natl Cancer Inst 85:676, 1993 (letter)
19. Durrelman S, Simon R: Planning and monitoring of equivalence studies. Biometrics 46:329-336, 1990
20. Cutler SJ, Ederer F: Maximum utilization of the life table in analyzing survival. J Chron Dis 8:699-712, 1958
21. Hanke B, Myers M: Evaluating differences in survival between two groups of patients. J Chron Dis 24:523-531, 1971
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 30:248-275, 1972
24. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc B 34:205-207, 1972
25. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203-223, 1965
26. Tarone RE, Ware J: On distribution-free tests for equality of survival distributions. Biometrika 62:679-682, 1977
27. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
28. Sarosy G, Kohn E, Link C, et al: Dose intensity: Is there a dose-response relationship for Taxol? Alexandria, VA, Second NCI Workshop on Taxol and Taxus, 1992
29. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 388)
30. Peretz T, Sulket A, Challet R, et al: A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Proc Eur J Cancer 31A:s75, 1995 (abstr 345)
31. Holmes FA, Valero V, Buzdar A, et al: Final results: Randomized phase III trials of paclitaxel by 3-hr versus 96-hr infusion in patients (pt) with met breast cancer (MBC): The long & short of it. Proc Am Soc Clin Oncol 17:110a, 1998 (abstr 426)